{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:42:23Z","timestamp":1787013743781,"version":"build-2736575974"},"reference-count":33,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2016,5,12]],"date-time":"2016-05-12T00:00:00Z","timestamp":1463011200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"Konya Training and Research Hospital-Education and Research Fund"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J of Rheum Dis"],"published-print":{"date-parts":[[2018,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Soluble urokinase plasminogen activator receptor (su\n                      <jats:styled-content style=\"fixed-case\">PAR<\/jats:styled-content>\n                      ), a new biomarker, is a soluble form of membrane\u2010bound receptors secreted from different immune cells. The aim of the present study is to determine plasma su\n                      <jats:styled-content style=\"fixed-case\">PAR<\/jats:styled-content>\n                      levels in Beh\u00e7et's disease and their correlation with disease activity.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Thirty Beh\u00e7et's disease patients determined according to the International Study Group criteria for Beh\u00e7et's disease diagnosis and 41 healthy subjects were included in the present study. Micro\u2010enzyme\u2010linked immunosorbent assay was employed to obtain quantitative data. Data of both groups were statistically analyzed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The comparison of C\u2010reactive protein and su\n                      <jats:styled-content style=\"fixed-case\">PAR<\/jats:styled-content>\n                      plasma levels of the control and Beh\u00e7et's disease group revealed statistically significant differences (respectively,\n                      <jats:italic>P<\/jats:italic>\n                      = 0.003 &lt; 0.05 and\n                      <jats:italic>P<\/jats:italic>\n                      = 0.020 &lt; 0.05). However, plasma su\n                      <jats:styled-content style=\"fixed-case\">PAR<\/jats:styled-content>\n                      levels related with disease activity revealed no statistically significant differences (\n                      <jats:italic>P<\/jats:italic>\n                      &gt; 0.05).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      The present study is the first study analyzing su\n                      <jats:styled-content style=\"fixed-case\">PAR<\/jats:styled-content>\n                      levels in Beh\u00e7et's disease patients and their correlation with disease activity. However, further prospective studies with larger patient series using su\n                      <jats:styled-content style=\"fixed-case\">PAR<\/jats:styled-content>\n                      as a new plasma biomarker are required to diagnose and monitor Behcet's disease and to support the findings of the present study.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/1756-185x.12873","type":"journal-article","created":{"date-parts":[[2016,5,12]],"date-time":"2016-05-12T09:08:23Z","timestamp":1463044103000},"page":"866-870","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Plasma\u2010soluble urokinase plasminogen activator receptor (su\n                    <scp>PAR<\/scp>\n                    ) levels in Beh\u00e7et's disease and correlation with disease activity"],"prefix":"10.1111","volume":"21","author":[{"given":"Gulcan","family":"Saylam Kurtipek","sequence":"first","affiliation":[{"name":"Department of Dermatology Konya Training and Research Hospital Konya Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Recep","family":"Kesli","sequence":"additional","affiliation":[{"name":"Department of Microbiology Afyon Kocatepe University Faculty of Medicine Afyonkarahisar Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatma","family":"Tuncez Akyurek","sequence":"additional","affiliation":[{"name":"Department of Dermatology Sel\u00e7uk University Faculty of Medicine Konya Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fikret","family":"Akyurek","sequence":"additional","affiliation":[{"name":"Department of Biochemistry Sel\u00e7uk University Faculty of Medicine Konya Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arzu","family":"Ataseven","sequence":"additional","affiliation":[{"name":"Department of Dermatology Konya Training and Research Hospital Konya Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuksel","family":"Terzi","sequence":"additional","affiliation":[{"name":"Department of Biostatistics 19 May University Samsun Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,5,12]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/38.12.1171"},{"key":"e_1_2_7_3_1","first-page":"1078","article-title":"Criteria for diagnosis of Beh\u00e7et's disease","volume":"335","author":"International Study Group for Beh\u00e7et's Disease","year":"1990","journal-title":"Lancet"},{"key":"e_1_2_7_4_1","first-page":"402","article-title":"Vascular involvement in Beh\u00e7et's disease","volume":"19","author":"Ko\u00e7 Y","year":"1992","journal-title":"J Rheumatol"},{"key":"e_1_2_7_5_1","first-page":"305780","article-title":"Pathological and immunological developments in Behcet's disease","volume":"2012","author":"Tursen U","year":"2012","journal-title":"Patholog Res Int"},{"key":"e_1_2_7_6_1","first-page":"261989","article-title":"Development of immunopathogenesis strategies to treat Behcet's disease","volume":"2012","author":"Kose O","year":"2012","journal-title":"Patholog Res Int"},{"key":"e_1_2_7_7_1","first-page":"493015","article-title":"Pathophysiology of the Behcet's disease","volume":"2012","author":"Tursen U","year":"2012","journal-title":"Patholog Res Int"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2004.00907.x"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1155\/2009\/504294"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.4137\/BMI.S9460"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1186\/cc10577"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12107"},{"key":"e_1_2_7_13_1","first-page":"209","article-title":"Beh\u00e7et Hastalar\u0131nda Leptin D\u00fczeyleri","volume":"44","author":"\u0130nan\u0131r I","year":"2010","journal-title":"Turkderm"},{"key":"e_1_2_7_14_1","first-page":"34","article-title":"Beh\u00e7et hastal\u0131\u011f\u0131nda imm\u00fcnolojik aktivasyon belirte\u00e7leri","volume":"2","author":"Bayaz\u0131t N","year":"2008","journal-title":"T\u00fcrk Dermatoloji Dergisi"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-012-2613-1"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.4137\/BMI.S6876"},{"key":"e_1_2_7_17_1","first-page":"240","article-title":"Soluble urokinase plasminogen activator receptor levels in tuberculosis patients at high risk for multidrug resistance","volume":"2012","author":"Mardining Raras TY","year":"2012","journal-title":"Tuberc Res Treat"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.3109\/00365521.2012.699549"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1515\/cclm-2012-0221"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10753-009-9152-0"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1478-3231.2011.02665.x"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2012.07.018"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-7-134"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-013-0540-9"},{"key":"e_1_2_7_25_1","first-page":"1981","article-title":"The prognostic value of plasma soluble urokinase plasminogen activator receptor (suPAR) levels in stage III ovarian cancer patients","volume":"24","author":"Begum FD","year":"2004","journal-title":"Anticancer Res"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcrc.2013.08.005"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinbiochem.2012.11.004"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinbiochem.2011.07.006"},{"key":"e_1_2_7_29_1","first-page":"1","article-title":"Circulatinglevels of urokinase\u2010typeplasminogenactivator (uPA) and its soluble receptor (suPAR) in patients with atopic eczema\/dermatitis syndrome","volume":"33","author":"Kasperska\u2010Zajac A","year":"2010","journal-title":"Inflammation"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.trsl.2013.07.003"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.3109\/1354750X.2012.728623"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0969-2126(99)80023-9"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1097\/MAJ.0b013e3182959a18"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4362.1986.tb02232.x"}],"container-title":["International Journal of Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2F1756-185X.12873","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2F1756-185X.12873","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1756-185X.12873","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T11:16:18Z","timestamp":1695554178000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1756-185X.12873"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5,12]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["10.1111\/1756-185X.12873"],"URL":"https:\/\/doi.org\/10.1111\/1756-185x.12873","archive":["Portico"],"relation":{},"ISSN":["1756-1841","1756-185X"],"issn-type":[{"value":"1756-1841","type":"print"},{"value":"1756-185X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,5,12]]},"assertion":[{"value":"2016-05-12","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}